Research publications | Alfred Health

Multicentre stepped-wedge cluster randomised controlled trial of an antimicrobial stewardship programme in residential aged care: protocol for the START trial.

Jokanovic N, Haines T, Cheng AC, Holt KE, Hilmer SN, Jeon YH, Stewardson AJ, Stuart RL, Spelman T, Peel TN, Peleg AY; START Trial Group

(2021), BMJ Open, 11(3), e046142

DOI: 10.1136/bmjopen-2020-046142

Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.

Hensen L, Nguyen THO, Rowntree LC, Damelang T, Koutsakos M, Aban M, Hurt A, Harland KL, Auladell M, van de Sandt CE, Everitt A, Blacker C, Oyong DA, Loughland JR, Webb JR, Wines BD, Hogarth PM, Flanagan KL, Plebanski M, Wheatley A, Chung AW, Kent SJ, Mill

(2021), P NATL ACAD SCI USA, 118(41), e2109388118

DOI: 10.1073/pnas.2109388118

Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.

Hellard M, Pedrana A, Draper B

(2021), LANCET GASTROENTEROL, 6(6), 414-6

DOI: 10.1016/s2468-1253(21)00135-7

Effect of Rosuvastatin therapy on biomarkers of inflammation and immune activation in people with Human Immunodeficiency Virus at intermediate cardiovascular risk.

Hearps AC, Angelovich TA, Trevillyan JM, Wong ME, Calmy A, Hoy JF, Jaworowski A

(2021), J Infect Dis, 224(4), 667-72

DOI: 10.1093/infdis/jiaa775

Letter to the Editor: Recommendations for implementing hepatitis C virus care in homeless shelters: The stakeholder perspective.

Harney B, McColl R, Pedrana A, Morrison E, Doyle J, Hellard M, Higgs P

(2021), Hepatol Commun, 5(1), 146-7

DOI: 10.1002/hep4.1616

Routine testing for syphilis and other bacterial sexually transmissible infections is required among people in prison.

Harney B, Doyle J, Hellard M, Stoové M, Winter R

(2021), Sex Transm Dis, 48(10), e153

DOI: 10.1097/olq.0000000000001532

Letter in response: Psychiatrists can treat hepatitis C.

Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS

(2021), J VIRAL HEPATITIS, 28(12), 1765-6

DOI: 10.1111/jvh.13619

Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.

Goutzamanis S, Spelman T, Harney B, Dietze P, Stoové M, Higgs P, Thompson A, Doyle JS, Hellard M; Treatment, Prevention Study group.

(2021), J VIRAL HEPATITIS, 28(7), 1068--77

DOI: 10.1111/jvh.13516

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study.

Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P; Treatment and Prevention Study group.

(2021), Harm Reduct J, 18(1), 73

DOI: 10.1186/s12954-021-00516-1

Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.

Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group

(2021), Int J Drug Policy, 87, 102983

DOI: 10.1016/j.drugpo.2020.102983

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.

Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten

(2021), EBiomedicine, 74, 103729

DOI: 10.1016/j.ebiom.2021.103729

Outcomes of the CT2 Study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.

Draper B, Htay H, Pedrana A, Yee WL, Howell J, Kyi KP, Naing W, Aung KS, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M

(2021), Liver Int, 41(11), 2578-89

DOI: 10.1111/liv.14983

Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.

Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME

(2021), Clin Infect Dis, 73(7), e2164–e2172

DOI: 10.1093/cid/ciaa1500

Health service utilisation and experiences of stigma among people who inject drugs in Melbourne, Australia.

Djordjevic F, Ryan K, Gunn J, Brener L, O'Keefe D, Draper B, Schroeder S, Gold J, Treloar C, Broady T, Dietze P, Hellard M, Pedrana A

(2021), J VIRAL HEPATITIS, 28(12), 1738-43

DOI: 10.1111/jvh.13612

Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.

Chan K, Elsum I, Gold J, Layton C, Accadia L, Bryant M, Gunn J, Djordjevic F, Purcell I, Dicka J, Forrest M, Crawford S, Hellard M, Pedrana A; Eliminate Hepatitis C Partnership

(2021), J VIRAL HEPATITIS, 28(3), 569-572

DOI: 10.1111/jvh.13447

Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort

Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group

(2021), Int J Drug Policy, 96, 103422

DOI: 10.1016/j.drugpo.2021.103422

Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.

Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L, Morris M, Ong JJ, Platt L, Sack-Davis R, van Santen DK, Solomon SS, Sypsa V, Valencia J, Van Den Boom W, Walker JG, Ward Z, Stone J, Vickerman P;

(2021), Lancet Public Health, 6(5), E309-E323

DOI: 10.1016/s2468-2667(21)00013-x

Safety and utility of kidney biopsy in patients with estimated glomerular filtration rate < 30 ml/min/1.73 m2

Asad RA, Valson AT, Kavitha V, Korula A, Eapen A, Rebekah G, Jacob S, Pathak H, Alexander S, Mohapatra A, David VG, Varughese S, Tamilarasi V, Basu G

(2021), Nephrology, 26(8), 659-68

DOI: 10.1111/nep.13879

Disinvestment in the presence of uncertainty: Description of a novel, multi-group, disinvestment trial design and protocol for an application to reduce or cease use of mobilisation alarms for preventing falls in hospitals

Haines TP, Botti M, Brusco N, O'Brien L, Redley B, Bowles KA, Hutchinson A, Mitchell D, Jellett J, Steen K, Boyd L, Webb-St Mart M, Raymond M, Hunter P, Russo P, Bonnici R, Pu D, Sevenhuysen S, Davies V, Shorr R

(2021), PLoS One, 16(12), e0261793

DOI: 10.1371/journal.pone.0261793

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Menon S, Davies A, Frentzas S, Hawkins CA, Segelov E, Day D, Markman B

(2021), Cancer Reports, 5(2), e1465

DOI: 10.1002/cnr2.1465